日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

针对骨髓增生性肿瘤的基于精氨酸酶 1 和 PD-L1 衍生肽的疫苗:首次人体临床试验

Jacob Handlos Grauslund, Morten Orebo Holmström, Evelina Martinenaite, Thomas Landkildehus Lisle, Hannah Jorinde Glöckner, Daniel El Fassi, Uffe Klausen, Rasmus E J Mortensen, Nicolai Jørgensen, Lasse Kjær, Vibe Skov, Inge Marie Svane, Hans Carl Hasselbalch, Mads Hald Andersen

Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial

表观遗传疗法联合针对共享肿瘤抗原的多表位癌症疫苗治疗高风险骨髓增生异常综合征 - I 期临床试验

Staffan Holmberg-Thydén, Inge Høgh Dufva, Anne Ortved Gang, Marie Fredslund Breinholt, Lone Schejbel, Mette Klarskov Andersen, Mohammad Kadivar, Inge Marie Svane, Kirsten Grønbæk, Sine Reker Hadrup, Daniel El Fassi

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression

更正:患有骨髓增生性肿瘤的患者存在高频率的 CD8 T 细胞-血小板聚集体,与 T 细胞抑制有关

Ana Micaela Carnaz Simões, Morten Orebo Holmström, Pia Aehnlich, Anne Rahbech, Marlies J W Peeters, Aneta Radziwon-Balicka, Carlos Zamora, Tobias Wirenfeldt Klausen, Vibe Skov, Lasse Kjær, Christina Ellervik, Daniel El Fassi, Silvia Vidal, Hans Carl Hasselbalch, Mads Hald Andersen, Per Thor Straten

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

使用源自钙网蛋白外显子 9 突变的肽进行治疗性癌症疫苗接种可在 CALR 突变型慢性骨髓增生性肿瘤患者中诱导强烈的细胞免疫反应

Jacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, Uffe Klausen, Stine Emilie Weis-Banke, Daniel El Fassi, Claudia Schöllkopf, Mette Borg Clausen, Lise Mette Rahbek Gjerdrum, Marie Fredslund Breinholt, Julie Westerlin Kjeldsen, Morten Hansen, Steffen Koschmieder, Nicolas Chat